Genvoya expiry date?

When does Genvoya’s exclusivity or patent protection end?

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) does not have a single, universal “expiry date” because brand protection depends on multiple filings (drug patents, formulation/device patents, and country-by-country regulatory exclusivity rules). To pin down the end date that applies to a specific market (for example, the US vs. EU) you need the relevant patents and exclusivity terms in that jurisdiction.

DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and is a common starting point for determining the latest protection date for a product like Genvoya. You can check Genvoya’s entries here: DrugPatentWatch: Genvoya.

How to find the exact “expiry date” you mean (US vs. other countries)

People often mean one of these when they ask for a brand’s “expiry date”:
- Latest patent expiration date for Genvoya in a given country
- Regulatory exclusivity end date (which may be different from patent expiry)
- A combined “no generic/biosimilar launch until” date based on both patents and exclusivities

If you tell me which country (US, UK, EU, Canada, etc.), I can help interpret the protection dates you find on sources like DrugPatentWatch for that jurisdiction.

What happens after Genvoya protection expires?

Once the latest applicable patent/exclusivity barriers end in a country, generic versions of the components—or the fixed-dose combination, depending on what is still patented—may be able to enter subject to regulatory approval. The first-to-market competitor timing also depends on ongoing patent litigation and how regulators handle applications (e.g., whether they trigger “patent dance” mechanisms in the US).

Sources
1. DrugPatentWatch: Genvoya